Laboratorios Farmaceuticos RoviXMAD:ROVI -1.45%97 Pretax Margin % is 8.06% as of Mar. 2026, which is 60% below its 10-year median of 20.28. GuruFocus rates XMAD:ROVI with a GF Score™ of 97/100 and a GF Value™ of €50.97 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 953 Drug Manufacturers companies, Laboratorios Farmaceuticos Rovi ranks better than 85.94% on this metric.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Laboratorios Farmaceuticos Rovi Pretax Margin % Related Terms
Laboratorios Farmaceuticos Rovi Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:ROVI vs ZTS, UTHR, VTRS: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorios Farmaceuticos Rovi's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laboratorios Farmaceuticos Rovi Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Laboratorios Farmaceuticos Rovi's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Laboratorios Farmaceuticos Rovi (XMAD:ROVI) has a Pretax Margin % of 8.06% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. This is 60% below median its historical median of 20.28. Over the past decade, Laboratorios Farmaceuticos Rovi's Pretax Margin % has ranged from 5.50 to 31.55. According to the industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #134 out of 953 companies in the Drug Manufacturers industry, placing it in the top 14.1%.
Is Laboratorios Farmaceuticos Rovi's Pretax Margin % too high?
Laboratorios Farmaceuticos Rovi's current Pretax Margin % of 8.06% is 60% below median its 10-year median of 20.28. Over the past 10 years, this metric has ranged from a low of 5.50 to a high of 31.55. The Drug Manufacturers industry median Pretax Margin % is 7.30. Laboratorios Farmaceuticos Rovi's value of 8.06% is 10.4% above this industry median. Based on the distribution chart, Laboratorios Farmaceuticos Rovi ranks #134 out of 953 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 97/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #134 out of 953 companies for Pretax Margin %. This places Laboratorios Farmaceuticos Rovi in the top 14% of its industry — outperforming the majority of peers. The industry median Pretax Margin % is 7.30. Laboratorios Farmaceuticos Rovi's value of 8.06% is 10.4% above this benchmark. Historically, Laboratorios Farmaceuticos Rovi's own Pretax Margin % has ranged from 5.50 to 31.55 over the past decade. While the company's 10-year median is 20.28 vs. the industry median of 7.30, Laboratorios Farmaceuticos Rovi has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.30, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Laboratorios Farmaceuticos Rovi's current Pretax Margin % of 8.06% is 10.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Laboratorios Farmaceuticos Rovi's current Pretax Margin % is 8.06%, which is 60% below median its own 10-year median of 20.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi (XMAD:ROVI) is currently considered Modestly Overvalued. The stock's GF Value™ is €50.97, compared to a current price of €57.85 — trading 13.5% above its estimated fair value. The current Pretax Margin % is 8.06%, which is 60% below median its 10-year median of 20.28 and 10.4% above the Drug Manufacturers industry median of 7.30. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 97/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (XMAD:ROVI), the current Pretax Margin % is 8.06% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Overvalued in 2026?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be overvalued.
The current stock price of €57.85 is trading 13.5% above its estimated GF Value™ of €50.97.
GuruFocus considers Laboratorios Farmaceuticos Rovi to be Modestly Overvalued.
Key valuation signals for XMAD:ROVI:
Pretax Margin %: 8.06% (60% below median its 10-year median of 20.28)
GF Value™: €50.97 vs. price of €57.85 (13.5% above fair value)
Industry Position: 10.4% above the Drug Manufacturers median (#134 of 953)
No single metric tells the full story. See the XMAD:ROVI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Laboratorios Farmaceuticos Rovi Business Description
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
97GF Score
Get the complete analysis for XMAD:ROVI
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:ROVI has been successfully added to your 
